Streptococcus porcinus is usually associated with swine. Because we have received several isolates from human sources that had cross-reacted with commercial group B streptococcal reagents, we examined several commercial kits to determine the extent of this cross-reaction. Fifteen reference and 15 clinical strains of S. porcinus were tested for cross-reactions with group B streptococcal reagents from 12 different commercial kits. Cross-reactions were detected with all group B reagents, but the number of cross-reactions varied with each kit. We recommend that manufacturers of reagents designed to identify group B streptococci by serologic methods test their reagents for cross-reactions with selected S. porcinus cultures or antigens.
Current recommendations for establishing the specificity of streptococcal grouping reagents, including the rapid antigen tests for detecting group A and B streptococci, include strains representing group A, B, C, D, F, and G streptococci (2, 3, 5) . The beta-hemolytic strains of Streptococcus porcinus (groups E, P, U, and V) were not included because these strains are seldom isolated from human sources (4) . S. porcinus is usually associated with cervical lymph node infections in swine and is rarely reported from human infections. In clinical settings, the beta-hemolytic streptococci are most often identified with commercial grouping kits. Identification is by either coagglutination or latex agglutination with extraction of the antigen from the organism with either an enzyme or nitrous acid.
We previously reported an increased incidence of isolates of S. porcinus from the genitourinary tracts of reproductive-age women (4) . Recently, several S. porcinus cultures have been submitted to the Centers for Disease Control and Prevention (CDC) Streptococcus Reference Laboratory because they had reacted with group B slide agglutination reagents of commercial streptococcal grouping kits. Since antimicrobial therapy generally is provided to pregnant women with group B streptococci identified from the genitourinary tract, incorrectly identifying S. porcinus as a group B streptococcus may have some clinical significance. We examined several commercially available streptococcal grouping kits for agglutination reactions with S. porcinus. All strains of S. porcinus used in this study were obtained from the Streptococcus Reference Laboratory, CDC. Fifteen reference strains, which included representatives of groups E, P, U, and V and new groups 1, 2, and 3 (NG1, NG2, and NG3), were used (1). Also included were 15 clinical strains of S. porcinus (2 group P, 12 NG1, and 1 with no group antigen). All clinical strains were extracted by the Lancefield extraction procedure and tested with CDC-prepared group antisera in a capillary precipitin test (6) . Eight commercial streptococcal grouping kits and four kits designed to identify only group B streptococci were tested for crossreactions with S. porcinus. Two unabsorbed lots of CDC streptococcal group B grouping antisera were available for testing. Lancefield extracts of S. porcinus SS-995, SS-996, and 1256-95 showed cross-reactions with one lot. Adsorption experiments failed to remove the S. porcinus cross-reaction in CDC unabsorbed group B antiserum. Aliquots of unabsorbed group B antiserum were absorbed with S. porcinus cells of strains SS-995, SS-996, and 1256-95 in ratios of 1 part cells to 5, 10, and 20 parts antiserum. Cells and antisera were mixed by vortexing and held at room temperature for 30 min before being separated by centrifugation. Only absorption at the 1:5 ratio of cells to antiserum completely removed all the cross-reactions, but absorptions with each strain at all three ratios of cells to antiserum removed or greatly reduced the sensitivity of the reaction of the group B antiserum. This indicates some sharing of antigenic entities between S. porcinus and group B streptococci. This was seen in agar gel diffusion studies in which Lancefield extracts of S. porcinus (strain 1256-95) and group B streptococci (strain SS-1073) showed lines of partial identity when tested with unabsorbed group B antisera.
Some confusion can occur in distinguishing between S. porcinus and group B streptococci. Both are bacitracin negative, CAMP positive (7), and beta-hemolytic. Zones of hemolysis are much more pronounced with S. porcinus than with group B streptococci (Fig. 1) . The two types of streptococci can be differentiated phenotypically with the pyrrolydonlarylamidase (PYRase) and Voges-Proskauer tests; S. porcinus is positive in both tests, while group B streptococci are negative in both.
Our results indicate that strains that react with the group B reagents of commercial kits, are CAMP positive and bacitracin negative, and produce a wide zone of hemolysis on 5% sheep blood agar may be S. porcinus. The identification of these strains may be confirmed by the PYRase and Voges-Proskauer tests.
Not all lots of CDC-prepared or commercially prepared group B streptococcal grouping antisera cross-react with S. porcinus strains. We do not know the incidence of S. porcinus strains in humans. We expect that it is currently quite low, but no studies seeking to identify these streptococci have been done. We recommend that all future lots of group B reagents be tested for potential cross-reactions with S. porcinus group E, P, U, V, and NG1 strains. Strains with representative S. porcinus group antigens are available from us upon request. Reference strains b Numbers in parentheses are numbers of strains that reacted with the RIM experimental lot with additional absorption.
